Health Care & Life Sciences » Biotechnology | Cyclacel Pharmaceuticals Inc.

Cyclacel Pharmaceuticals Inc. | Mutual Funds

Mutual Funds that own Cyclacel Pharmaceuticals Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Vanguard Total Stock Market Index Fund
262,933
2.19%
0
0%
07/31/2018
Vanguard Extended Market Index Fund
106,172
0.89%
0
0%
07/31/2018
Fidelity Spartan Extended Market Index Fund
17,747
0.15%
0
0%
07/31/2018
Vanguard Balanced Index Fund
3,392
0.03%
0
0%
07/31/2018
Fidelity Nasdaq Composite Index
2,985
0.03%
0
0%
07/31/2018
DFA US Vector Equity Portfolio
2,700
0.02%
0
0%
04/30/2018
2,579
0.02%
0
0.01%
09/05/2018
Fidelity Spartan Total Market Index Fund
960
0.01%
0
0%
07/31/2018
iShares Core S&P Total US Stock Market ETF
796
0.01%
0
0%
09/06/2018

About Cyclacel Pharmaceuticals

View Profile
Address
200 Connell Drive
Berkeley Heights New Jersey 07922
United States
Employees -
Website http://www.cyclacel.com
Updated 07/08/2019
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It uses cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted medicines for cancer and other proliferative diseases. The company builds a diversified biopharmaceutical business, which is focused in hematology and oncology based on a pipeline of novel drug candidates.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.